Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.67 |
| ▸ | CFD | P00746 | 2/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.62 |
| ▸ | HPGD | P15428 | 4/20 | 0.62 |
| ▸ | TSHR | P16473 | 3/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.62 |
| ▸ | ESR1 | P03372 | 2/20 | 0.62 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.62 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.62 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.62 |
| ▸ | GGT1 | P19440 | 1/20 | 0.62 |
| ▸ | BLM | P54132 | 1/20 | 0.62 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25027 | 0.89 | CFD (0.73) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL10119527 | 0.87 | CFD (0.51) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL18136334 | 0.83 | CFD (0.87) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL16719151 | 0.82 | CFD (0.88) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL342690 | 0.81 | ALDH1A1 (0.62) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL8895553 | 0.81 | ACHE (0.59) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL16719158 | 0.81 | CFD (0.73) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL12205977 | 0.81 | CFD (0.50) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL3453790 | 0.81 | TSHR (0.58) | KDM4ECFDHSD17B10ALDH1A1HPGD | |
| SCHEMBL16719152 | 0.81 | CFD (0.76) | KDM4ECFDHSD17B10ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8742138-B2 | Compounds as hypoxia mimetics, and compositions and uses thereof | BETTA PHARMACEUTICALS CO., LTD. (CN) | 2014-06-03 | — | — | US | disclosed |
| US-8324405-B2 | Chromene derivatives and use thereof as HIF hydroxylase activity inhibitors | FIBROGEN, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | BEIJING BETTA PHARMACEUTICALS CO., LTD. (CN) | 2012-07-05 | — | — | US | disclosed |
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. | 2010-12-30 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| EP-0950669-B1 | Method of catalytic crosslinking of polymers and two-pack composition used therein | ROHM & HAAS (US) | 2004-09-08 | — | — | EP | disclosed |
| US-6306991-B1 | TWO PART COATING COMPOSITION WITH TWO CONTAINERS, OXIDATIVE POLYMERS WITH CROSSLINKABLE FUNCTIONAL GROUPS | ROHM AND HAAS COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6149977-A | CONTACTING THE OXIDATIVE POLYMER WITH A CATALYTIC AMOUNT OF AN OXIDIZING ENZYME, SUCH AS HORSERADISH PEROXIDASE. | ROHM AND HAAS COMPANY (US) | 2000-11-21 | — | — | US | disclosed |
| EP-0950669-A2 | Method of catalytic crosslinking of polymers and two-pack composition used therein | ROHM AND HAAS COMPANY (US) | 1999-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331400-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | HIF1AN, HIF1A, EGLN2 | KDM4E 550/4885CFD 3665/4885HSD17B10 93/4885 |
| US-20120172399-A1 | COMPOUNDS AS HYPOXIA MIMETICS, AND COMPOSIITONS AND USES THEREOF | HIF1AN, HIF1A, EGLN3 | KDM4E 1763/4885CFD 1704/4885HSD17B10 2669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.